Patho II_PUD_CBL

Introduction

Peptic Ulcer Disease (PUD) is a significant gastrointestinal condition characterized by erosion in the lining of the GI tract. The presentation of PUD includes the pathology related to H. pylori infection and NSAID use, as well as various risk factors and clinical implications.

Objectives

  1. Understand the mucosal defense system's role in protecting the gastric epithelium.

  2. Describe the pathology behind H. pylori and NSAID-induced ulcers.

  3. Identify risk factors and the clinical trajectory of peptic ulcer disease.

  4. Apply pathophysiological knowledge to a patient case regarding gastroesophageal reflux disease (GERD).

Epidemiology

  • Incidence and Prevalence: Varied due to factors like H. pylori infection, NSAID usage, and smoking.

  • Quality of Life Impact: PUD is a common GI disorder leading to diminished quality of life, work loss, and high healthcare costs.

  • Demographics: Similar prevalence between genders; increased mortality and prevalence seen in individuals over 65 years old and disparities in infection rates among African American and Hispanic populations.

Pathophysiology

  • PUD involves ulcers ≥ 5 mm that penetrate the muscularis mucosa with chronic recurrence characterized by exacerbations and remissions.

  • Locations of Ulcers: Most commonly occur in the duodenum and stomach, with rare occurrences in the esophagus, colon, ileum, and jejunum.

Common Causes of PUD

  • Most Common: H. pylori infection, NSAID use.

  • Less Common: Stress-related mucosal damage, idiopathic causes, hypersecretion of gastric acid, and certain viral infections.

Risk Factors for Ulcer Recurrence

  • Smoking, alcohol use, gastric acid hypersecretion, and non-adherence to medication regimens contribute to increased risk alongside NSAID and H. pylori.

Pathophysiological Contributors

  • An imbalance between acid secretion and protective mechanisms leads to ulcer formation.

  • Key players include:

    • Gastric Acid: Secreted by parietal cells, important in digestive processes but can disrupt mucosal integrity.

    • Pepsin: Activated enzyme contributing to ulcer formation.

Protective Mechanisms

  1. Mucosal defense systems consisting of a mucus-bicarbonate layer.

  2. Prostaglandins that foster epithelial resistance and facilitate cell renewal.

  3. Continuous blood flow to preserve the sub-epithelial barrier.

Helicoacter Pylori Mechanisms

  • Survival Mechanisms: Flagellated, able to move past acidic conditions and produce urease to neutralize gastric acid. Causes chronic gastritis and is implicated in ulcer development and certain cancers. Transmission is primarily fecal-oral.

NSAID-Induced Ulcers

  • Occurs due to the inhibition of protective prostaglandin synthesis and direct irritation of gastric epithelium through acidic properties.

  • Increased risk with age, history of ulcers, and concurrent use of other medications.

Clinical Presentation

  • Symptoms may include epigastric pain, nausea, and dyspepsia, with differences between gastric and duodenal ulcers.

  • Alarm symptoms include unexplained weight loss and anemia, necessitating further evaluation.

Diagnostic Testing

  • Tests include endoscopic biopsy, rapid urease tests, antibody tests, urea breath tests, and fecal antigen tests to confirm H. pylori infection.

Complications

  • Can lead to severe complications such as GI bleeding, perforation, obstruction, and, in rare cases, MALT lymphoma.

Case Studies

  • An example patient may present with gastrointestinal bleeding associated with NSAID use and previous ulcers. Understanding the pathophysiology helps in identifying treatment approaches and risk factors relevant to their condition.